Health Catalyst, Inc. (HCAT)
| Market Cap | 119.66M -53.9% |
| Revenue (ttm) | 292.25M -7.5% |
| Net Income | -264.82M |
| EPS | -3.68 |
| Shares Out | 75.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 207,296 |
| Open | 1.590 |
| Previous Close | 1.590 |
| Day's Range | 1.585 - 1.640 |
| 52-Week Range | 0.955 - 3.800 |
| Beta | 1.56 |
| Analysts | Hold |
| Price Target | 1.83 (+15.09%) |
| Earnings Date | Aug 6, 2026 |
About HCAT
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. The company operates in two segments: Technology and Professional Services. It offers ignite data and analytics platform that provides clients a single comprehensive environment to integrate and organize data from their disparate software systems; and applications, a software analytics applications build for ignite platform to analyze clients face across clinical improvement, revenue and cost improvement, ambulatory operat... [Read more]
Financial Performance
In 2025, Health Catalyst's revenue was $311.14 million, an increase of 1.48% compared to the previous year's $306.58 million. Losses were -$177.97 million, 156.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for HCAT stock is "Hold." The 12-month stock price target is $1.83, which is an increase of 15.09% from the latest price.
News
Canaccord downgrades Health Catalyst to Hold on transformation risk
Canaccord downgraded Health Catalyst (HCAT) to Hold from Buy with a price target of $1.80, down from $3. The company is working through uncertainty around churn and down-sell risk among…
Health Catalyst downgraded to Hold from Buy at Canaccord
Canaccord analyst Richard Close downgraded Health Catalyst (HCAT) to Hold from Buy with a price target of $1.80, down from $3.
Health Catalyst price target lowered to $2 from $2.50 at Citi
Citi analyst Daniel Grosslight lowered the firm’s price target on Health Catalyst (HCAT) to $2 from $2.50 and keeps a Neutral rating on the shares. The firm updated its ratings…
Health Catalyst completes sale of Vitalware for $147M
Health Catalyst (HCAT) announced it closed the sale of Vitalware, through which the company conducted its Vitalware business, to Med-Metrix, a technology-enabled revenue cycle management company, on J...
Health Catalyst sees FY26 revenue $246M-$249M, consensus $266.93M
Sees FY26 adjusted EBITDA $18M to $18.5M.
Health Catalyst Earnings Call Transcript: Q2 2026
Q2 2026 results exceeded revenue and adjusted EBITDA guidance, driven by strong execution and the Vitalware divestiture, which enabled full debt repayment and a debt-free balance sheet. Updated 2026 guidance reflects the removal of Vitalware, ongoing migration costs, and continued investment in core technology and talent.
Health Catalyst Earnings release: Q2 2026
Health Catalyst released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Health Catalyst Quarterly report: Q2 2026
Health Catalyst has published its Q2 2026 quarterly earnings report on August 6, 2026.
Health Catalyst reports Q2 adjusted EPS 4c, consensus 3c
Reports Q2 revenue $70.49M, consensus $68.94M. The company recently closed the Vitalware divestiture and fully repaid its credit facility debt, which improves its balance sheet and provides flexibilit...
Health Catalyst sees Q3 revenue $55M-$56M, consensus $62.91M
Sees Q3 adjusted EBITDA $0-$500K.
Health Catalyst Reports Second Quarter 2026 Results
SALT LAKE CITY, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health sy...
Health Catalyst Completes Sale of Vitalware, Sharpening Its Focus as a Healthcare Intelligence Company
Company retires all credit facility debt; transaction reflects concentrating its technology on improving health system performance. SALT LAKE CITY, Aug. 6, 2026 /PRNewswire/ -- Health Catalyst, Inc. (...
Health Catalyst to Announce Second Quarter 2026 Operating Results and Host Conference Call on Thursday, August 6, 2026
SALT LAKE CITY, July 28, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health sy...
Health Catalyst price target raised to $2.50 from $1.75 at Citi
Citi raised the firm’s price target on Health Catalyst (HCAT) to $2.50 from $1.75 and keeps a Neutral rating on the shares. The firm adjusted ratings and targets in the…
Health Catalyst price target raised to $3 from $2 at Canaccord
Canaccord raised the firm’s price target on Health Catalyst (HCAT) to $3 from $2 and keeps a Buy rating on the shares. The firm updated its model heading into the…
Health Catalyst Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, and a proposal to phase out the classified board structure. Three proposals passed, while the board structure change did not reach the required approval threshold.
Health Catalyst price target raised to $1.75 from $1 at Wells Fargo
Wells Fargo analyst Stan Berenshteyn raised the firm’s price target on Health Catalyst (HCAT) to $1.75 from $1 and keeps an Equal Weight rating on the shares to account for…
Health Catalyst to Participate in Upcoming Investor Conference
SALT LAKE CITY, June 16, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health sy...
Med-Metrix Enters Into Definitive Agreement to Acquire Vitalware to Enhance Coding Accuracy and Net Revenue Yield
PARSIPPANY, N.J., June 4, 2026 /PRNewswire/ -- Med-Metrix, LLC ("Med-Metrix"), backed by Harvest Partners and A&M Capital Partners, today announced it has entered into a definitive agreement to acquir...
Health Catalyst to divest Vitalware to Med-Metrix for $147M in cash
Health Catalyst (HCAT) announced it has signed a definitive agreement to divest Vitalware and the Vitalware business unit, its mid-revenue cycle business, to Med-Metrix for a total consideration of $1...
Health Catalyst to Divest Vitalware for $147 Million, Accelerating Strategic Transformation
Health Catalyst today announced it has signed a definitive agreement to divest Vitalware, its mid-revenue cycle business, to Med-Metrix for $147 million.
Health Catalyst Proxy statement: Proxy filing
Health Catalyst filed a proxy statement on June 3, 2026, providing details for shareholder voting and corporate governance matters.
Health Catalyst Proxy statement: Proxy filing
Health Catalyst filed a proxy statement on June 3, 2026, providing details for shareholder voting and corporate governance matters.
Health Catalyst Proxy statement: Proxy filing
Health Catalyst filed a proxy statement on May 19, 2026, providing details for shareholder voting and corporate governance matters.
Health Catalyst price target lowered to $1.75 from $2 at Stephens
Stephens lowered the firm’s price target on Health Catalyst (HCAT) to $1.75 from $2 and keeps an Equal Weight rating on the shares. The combination of better-than-expected Q1 and below-consensus…